Li-Rong Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Li-Rong Yu has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
Zhijun Cao
Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, USA
8 shared publicationsRichard D. Beger
Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, USA
5 shared publicationsYuan Gao
U.S. Food and Drug Administration
5 shared publicationsJaclyn R. Daniels
Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, USA
3 shared publicationsLisa Pence
Division of Systems Biology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas
3 shared publications- Beate Kamlage
Metanomics Health GmbH, Berlin 10589, Germany
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in Cardio-Oncology
Baseline proteomic biomarkers for predicting chemotherapy-induced cardiotoxicity in breast cancer patients
Background: Currently, there are no reliable biomarkers to identify patients at high risk of treatment-related cardiotoxicity before initiation of chemotherapy. The aim of this study was to identify biomarkers for predicting asymptomatic decrease in left ventricular ejection fraction (LVEF) after doxorubicin (DOX)-based chemotherapy. Methods: A total of 83 breast cancer patients were treated with DOX-based chemotherapy. LVEF was measured before initiation and after completion of therapy. Thirty-nine patients were randomly assigned to the biomarker discovery cohort in which 9 had asymptomatic LVEF reduction (> 10% absolute reduction) after completing the therapy. The remaining 44 patients were grouped into the biomarker validation cohort in which 10 experienced asymptomatic LVEF reduction. Baseline plasma samples from the discovery cohort were analyzed by the SOMAscan proteomic assays for biomarker discovery. Biomarkers were verified using Olink proteomic assays in the validation cohort. Predictive models were generated using partial least squares discriminant analysis. Results: SOMAscan analysis for the biomarker discovery cohort revealed that baseline plasma levels of biglycan, carbonic anhydrase 6, cadherin-5, CD109, and thrombospondin-4 were higher, and cystatin-F was lower in the patients with asymptomatic LVEF reduction compared to those without. The levels of these proteins were verified in the validation cohort and associated with increased odds of asymptomatic LVEF reduction. Among the individual protein biomarkers, thrombospondin-4 achieved the highest accuracy of prediction for asymptomatic LVEF reduction (79.5% [95% CI, 64.7%-90.2%]). A predictive model using these 6 proteins, in combination with baseline LVEF, was able to predict asymptomatic LVEF reduction with a sensitivity of 80% (95% CI, 44.4%-97.5%), a specificity of 88% (95% CI, 72.5%-96.7%), and overall accuracy of 86% (95% CI, 72.6%-94.8%). Conclusions: These biomarkers and the model are potential new tools for the prediction of DOX-based treatment-related cardiotoxicity and the stratification of breast cancer patients before the initiation of chemotherapy. However, large-scale multi-center validation studies are required.
- 26 August 2026
- Published by Springer Nature in Cardio-Oncology
Open AccessBaseline proteomic biomarkers for predicting chemotherapy-induced cardiotoxicity in breast cancer patients
Background: Currently, there are no reliable biomarkers to identify patients at high risk of treatment-related cardiotoxicity before initiation of chemotherapy. The aim of this study was to identify biomarkers for predicting asymptomatic decrease in left ventricular ejection fraction (LVEF) after doxorubicin (DOX)-based chemotherapy. Methods: A total of 83 breast cancer patients were treated with DOX-based chemotherapy. LVEF was measured before initiation and after completion of therapy. Thirty-nine patients were randomly assigned to the biomarker discovery cohort in which 9 had asymptomatic LVEF reduction (> 10% absolute reduction) after completing the therapy. The remaining 44 patients were grouped into the biomarker validation cohort in which 10 experienced asymptomatic LVEF reduction. Baseline plasma samples from the discovery cohort were analyzed by the SOMAscan proteomic assays for biomarker discovery. Biomarkers were verified using Olink proteomic assays in the validation cohort. Predictive models were generated using partial least squares discriminant analysis. Results: SOMAscan analysis for the biomarker discovery cohort revealed that baseline plasma levels of biglycan, carbonic anhydrase 6, cadherin-5, CD109, and thrombospondin-4 were higher, and cystatin-F was lower in the patients with asymptomatic LVEF reduction compared to those without. The levels of these proteins were verified in the validation cohort and associated with increased odds of asymptomatic LVEF reduction. Among the individual protein biomarkers, thrombospondin-4 achieved the highest accuracy of prediction for asymptomatic LVEF reduction (79.5% [95% CI, 64.7%-90.2%]). A predictive model using these 6 proteins, in combination with baseline LVEF, was able to predict asymptomatic LVEF reduction with a sensitivity of 80% (95% CI, 44.4%-97.5%), a specificity of 88% (95% CI, 72.5%-96.7%), and overall accuracy of 86% (95% CI, 72.6%-94.8%). Conclusions: These biomarkers and the model are potential new tools for the prediction of DOX-based treatment-related cardiotoxicity and the stratification of breast cancer patients before the initiation of chemotherapy. However, large-scale multi-center validation studies are required.
- 26 July 2024
- Published by Springer Nature
- Vol. 2823, 225-239
Identification of Proteomic Biomarkers of Acetaminophen-Induced Hepatotoxicity Using Stable Isotope Labeling
Quantitative proteomics approaches based on stable isotopic labeling and mass spectrometry have been widely applied to disease research, drug target discovery, biomarker identification, and systems biology. One of the notable stable isotopic labeling approaches is trypsin-catalyzed 18O/16O labeling, which has its own advantages of low sample consumption, simple labeling procedure, cost-effectiveness, and absence of chemical reactions that potentially generate by-products. In this chapter, a protocol for 18O/16O labeling-based quantitative proteomics approach is described with an application to the identification of proteomic biomarkers of acetaminophen (APAP)-induced hepatotoxicity in rats. The protocol involves first the extraction of proteins from liver tissues of control and APAP-treated rats and digestion into peptides by trypsin. After cleaning of the peptides by solid-phase extraction, equal amounts of peptides from the APAP treatment and the control groups are then subject to trypsin-catalyzed 18O/16O labeling. The labeled peptides are combined and fractionated by off-line strong cation exchange liquid chromatography (SCXLC), and each fraction is then analyzed by nanoflow reversed-phase LC coupled online with tandem mass spectrometry (RPLC–MS/MS) for identification and quantification of differential protein expression between APAP-treated rats and controls. The protocol is applicable to quantitative proteomic analysis for a variety of biological samples.
- 26 July 2024
- Published by Springer Nature
- Vol. 2823, 225-239
Identification of Proteomic Biomarkers of Acetaminophen-Induced Hepatotoxicity Using Stable Isotope Labeling
Quantitative proteomics approaches based on stable isotopic labeling and mass spectrometry have been widely applied to disease research, drug target discovery, biomarker identification, and systems biology. One of the notable stable isotopic labeling approaches is trypsin-catalyzed 18O/16O labeling, which has its own advantages of low sample consumption, simple labeling procedure, cost-effectiveness, and absence of chemical reactions that potentially generate by-products. In this chapter, a protocol for 18O/16O labeling-based quantitative proteomics approach is described with an application to the identification of proteomic biomarkers of acetaminophen (APAP)-induced hepatotoxicity in rats. The protocol involves first the extraction of proteins from liver tissues of control and APAP-treated rats and digestion into peptides by trypsin. After cleaning of the peptides by solid-phase extraction, equal amounts of peptides from the APAP treatment and the control groups are then subject to trypsin-catalyzed 18O/16O labeling. The labeled peptides are combined and fractionated by off-line strong cation exchange liquid chromatography (SCXLC), and each fraction is then analyzed by nanoflow reversed-phase LC coupled online with tandem mass spectrometry (RPLC–MS/MS) for identification and quantification of differential protein expression between APAP-treated rats and controls. The protocol is applicable to quantitative proteomic analysis for a variety of biological samples.
- Top Cited PapersOpen Access
- 6 December 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 95 (51) , 18645-18654
Current Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples
Untargeted metabolomics is an analytical approach with numerous applications serving as an effective metabolic phenotyping platform to characterize small molecules within a biological system. Data quality can be challenging to evaluate and demonstrate in metabolomics experiments. This has driven the use of pooled quality control (QC) samples for monitoring and, if necessary, correcting for analytical variance introduced during sample preparation and data acquisition stages. Described herein is a scoping literature review detailing the use of pooled QC samples in published untargeted liquid chromatography-mass spectrometry (LC-MS) based metabolomics studies. A literature query was performed, the list of papers was filtered, and suitable articles were randomly sampled. In total, 109 papers were each reviewed by at least five reviewers, answering predefined questions surrounding the use of pooled quality control samples. The results of the review indicate that use of pooled QC samples has been relatively widely adopted by the metabolomics community and that it is used at a similar frequency across biological taxa and sample types in both small- and large-scale studies. However, while many studies generated and analyzed pooled QC samples, relatively few reported the use of pooled QC samples to improve data quality. This demonstrates a clear opportunity for the field to more frequently utilize pooled QC samples for quality reporting, feature filtering, analytical drift correction, and metabolite annotation. Additionally, our survey approach enabled us to assess the ambiguity in the reporting of the methods used to describe the generation and use of pooled QC samples. This analysis indicates that many details of the QC framework are missing or unclear, limiting the reader's ability to determine which QC steps have been taken. Collectively, these results capture the current state of pooled QC sample usage and highlight existing strengths and deficiencies as they are applied in untargeted LC-MS metabolomics.
- 6 December 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 95 (51) , 18645-18654
Top Cited PapersOpen AccessCurrent Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples
Untargeted metabolomics is an analytical approach with numerous applications serving as an effective metabolic phenotyping platform to characterize small molecules within a biological system. Data quality can be challenging to evaluate and demonstrate in metabolomics experiments. This has driven the use of pooled quality control (QC) samples for monitoring and, if necessary, correcting for analytical variance introduced during sample preparation and data acquisition stages. Described herein is a scoping literature review detailing the use of pooled QC samples in published untargeted liquid chromatography-mass spectrometry (LC-MS) based metabolomics studies. A literature query was performed, the list of papers was filtered, and suitable articles were randomly sampled. In total, 109 papers were each reviewed by at least five reviewers, answering predefined questions surrounding the use of pooled quality control samples. The results of the review indicate that use of pooled QC samples has been relatively widely adopted by the metabolomics community and that it is used at a similar frequency across biological taxa and sample types in both small- and large-scale studies. However, while many studies generated and analyzed pooled QC samples, relatively few reported the use of pooled QC samples to improve data quality. This demonstrates a clear opportunity for the field to more frequently utilize pooled QC samples for quality reporting, feature filtering, analytical drift correction, and metabolite annotation. Additionally, our survey approach enabled us to assess the ambiguity in the reporting of the methods used to describe the generation and use of pooled QC samples. This analysis indicates that many details of the QC framework are missing or unclear, limiting the reader's ability to determine which QC steps have been taken. Collectively, these results capture the current state of pooled QC sample usage and highlight existing strengths and deficiencies as they are applied in untargeted LC-MS metabolomics.
- 1 February 2023
- Published by Springer Nature
- p. 677-703
Doxorubicin Cardiotoxicity: Preclinical and Clinical Circulating Protein Markers
- 1 February 2023
- Published by Springer Nature
- p. 677-703
Doxorubicin Cardiotoxicity: Preclinical and Clinical Circulating Protein Markers
- Open Access
Microcalorimetric Investigations of Reversible Staphylococcal Enterotoxin Unfolding
Staphylococcal food poisoning (SFP) is a common food-borne illness often associated with contamination during food handling. The genes for Staphylococcal enterotoxin (SE) isoforms SEA and SEB are frequently detected in human nasal Staphylococcus aureus isolates and these toxins are commonly associated with SFP. Past studies described the resistance of preformed SE proteins to heat inactivation and their reactivation upon cooling in foods. Full thermodynamic analyses for these processes have not been reported, however. The thermal stabilities of SEA, SEB, and SEH and reversibility of unfolding in simple buffers were investigated at pH 4.5 and pH 6.8 using differential scanning calorimetry (DSC). SEA and SEB unfolding was irreversible at pH 6.8 and at least partially reversible at pH 4.5 while SEH unfolding was irreversible at pH 4.5 and reversible at pH 6.8. Additional studies showed maximum refolding for SEB at pH 3.5–4.0 and diminished refolding at pH 4.5 with increasing ionic strength. SE-stimulated secretion of interferon-gamma by human peripheral blood mononuclear cells was used to assess residual SE biological activity following heat treatments using conditions matching those used for DSC studies. The biological activities of SEB and SEH exhibited greater resistance to heat inactivation than that of SEA. The residual activities of heat-treated SEB and SEH were measurable but diminished further in the presence of reconstituted nonfat dry milk adjusted to pH 4.5 or pH 6.8. To different extents, the pH and ionic strengths typical for foods influenced the thermal stabilities of SEA, SEB, and SEH and their potentials to renature spontaneously after heat treatments.
Open AccessMicrocalorimetric Investigations of Reversible Staphylococcal Enterotoxin Unfolding
Staphylococcal food poisoning (SFP) is a common food-borne illness often associated with contamination during food handling. The genes for Staphylococcal enterotoxin (SE) isoforms SEA and SEB are frequently detected in human nasal Staphylococcus aureus isolates and these toxins are commonly associated with SFP. Past studies described the resistance of preformed SE proteins to heat inactivation and their reactivation upon cooling in foods. Full thermodynamic analyses for these processes have not been reported, however. The thermal stabilities of SEA, SEB, and SEH and reversibility of unfolding in simple buffers were investigated at pH 4.5 and pH 6.8 using differential scanning calorimetry (DSC). SEA and SEB unfolding was irreversible at pH 6.8 and at least partially reversible at pH 4.5 while SEH unfolding was irreversible at pH 4.5 and reversible at pH 6.8. Additional studies showed maximum refolding for SEB at pH 3.5–4.0 and diminished refolding at pH 4.5 with increasing ionic strength. SE-stimulated secretion of interferon-gamma by human peripheral blood mononuclear cells was used to assess residual SE biological activity following heat treatments using conditions matching those used for DSC studies. The biological activities of SEB and SEH exhibited greater resistance to heat inactivation than that of SEA. The residual activities of heat-treated SEB and SEH were measurable but diminished further in the presence of reconstituted nonfat dry milk adjusted to pH 4.5 or pH 6.8. To different extents, the pH and ionic strengths typical for foods influenced the thermal stabilities of SEA, SEB, and SEH and their potentials to renature spontaneously after heat treatments.
- 19 April 2022
- Published by Springer Nature
- Vol. 2486, 3-17
Mass Spectrometry–Based Proteomics for Biomarker Discovery
Proteomics plays a pivotal role in systems medicine, in which pharmacoproteomics and toxicoproteomics have been developed to address questions related to efficacy and toxicity of drugs. Mass spectrometry is the core technology for quantitative proteomics, providing the capabilities of identification and quantitation of thousands of proteins. The technology has been applied to biomarker discovery and understanding the mechanisms of drug action. Both stable isotope labeling of proteins or peptides and label-free approaches have been incorporated with multidimensional LC separation and tandem mass spectrometry (LC-MS/MS) to increase the coverage and depth of proteome analysis. A protocol of such an approach exemplified by dimethyl labeling in combination with 2D-LC-MS/MS is described. With further development of novel proteomic tools and increase in sample throughput, the full spectrum of mass spectrometry-based proteomic research will greatly advance systems medicine.
- 19 April 2022
- Published by Springer Nature
- Vol. 2486, 3-17
Mass Spectrometry–Based Proteomics for Biomarker Discovery
Proteomics plays a pivotal role in systems medicine, in which pharmacoproteomics and toxicoproteomics have been developed to address questions related to efficacy and toxicity of drugs. Mass spectrometry is the core technology for quantitative proteomics, providing the capabilities of identification and quantitation of thousands of proteins. The technology has been applied to biomarker discovery and understanding the mechanisms of drug action. Both stable isotope labeling of proteins or peptides and label-free approaches have been incorporated with multidimensional LC separation and tandem mass spectrometry (LC-MS/MS) to increase the coverage and depth of proteome analysis. A protocol of such an approach exemplified by dimethyl labeling in combination with 2D-LC-MS/MS is described. With further development of novel proteomic tools and increase in sample throughput, the full spectrum of mass spectrometry-based proteomic research will greatly advance systems medicine.
- 25 November 2021
- Published by Wolters Kluwer Health in Kidney360
- Vol. 2 (11) , 1716-1727
Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
Key Points: High throughput proteomics detected serum protein levels in patients with AKI-D who recovered kidney function. Novel predictive biomarkers of kidney recovery from patients with AKI-D were discovered. Potential biologic pathways associated with kidney remodeling, repair, and regeneration were suggested. Background: AKI requiring dialysis (AKI-D) is associated with prolonged hospitalization, mortality, and progressive CKD among survivors. Previous studies have examined only select urine or serum biomarkers for predicting kidney recovery from AKI. Methods: Serum samples collected on day 8 of randomized RRT from 72 patients enrolled in the Veteran's Affairs/National Institutes of Health Acute Renal Failure Trial Network study were analyzed by the SOMAscan proteomic platform to profile 1305 proteins in each sample. Of these patients, 38 recovered kidney function and dialysis was discontinued, whereas another 34 patients remained on dialysis by day 28. Results: Differential serum levels of 119 proteins, with 53 higher and 66 lower, were detected in samples from patients who discontinued dialysis, compared with patients who remained on dialysis by day 28. Patients were classified into tertiles on the basis of SOMAscan protein measurements for the 25 proteins most differentially expressed. The association of serum levels of each protein with kidney recovery was further evaluated using logistic regression analysis. Higher serum levels of CXCL11, CXCL2/CXCL3, CD86, Wnt-7a, BTK, c-Myc, TIMP-3, CCL5, ghrelin, PDGF-C, survivin, CA2, IL-9, EGF, and neuregulin-1, and lower levels of soluble CXCL16, IL1RL1, stanniocalcin-1, IL-6, and FGF23 when classified in tertiles were significantly associated with better kidney recovery. This significant association persisted for each of these proteins after adjusting for potential confounding risk factors including age, sex, cardiovascular SOFA score, congestive heart failure, diabetes, modality of intensive dialysis treatment, cause of AKI, baseline serum creatinine, day 8 urine volume, and estimated 60-day mortality risk. Conclusions: These results suggest concerted changes between survival-related proteins and immune-regulatory chemokines in regulating angiogenesis, endothelial and epithelial remodeling, and kidney cell regeneration, illustrating potential mechanisms of kidney recovery. Thus, this study identifies potential novel predictive biomarkers of kidney recovery in patients with AKI-D.
- 25 November 2021
- Published by Wolters Kluwer Health in Kidney360
- Vol. 2 (11) , 1716-1727
Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
Key Points: High throughput proteomics detected serum protein levels in patients with AKI-D who recovered kidney function. Novel predictive biomarkers of kidney recovery from patients with AKI-D were discovered. Potential biologic pathways associated with kidney remodeling, repair, and regeneration were suggested. Background: AKI requiring dialysis (AKI-D) is associated with prolonged hospitalization, mortality, and progressive CKD among survivors. Previous studies have examined only select urine or serum biomarkers for predicting kidney recovery from AKI. Methods: Serum samples collected on day 8 of randomized RRT from 72 patients enrolled in the Veteran's Affairs/National Institutes of Health Acute Renal Failure Trial Network study were analyzed by the SOMAscan proteomic platform to profile 1305 proteins in each sample. Of these patients, 38 recovered kidney function and dialysis was discontinued, whereas another 34 patients remained on dialysis by day 28. Results: Differential serum levels of 119 proteins, with 53 higher and 66 lower, were detected in samples from patients who discontinued dialysis, compared with patients who remained on dialysis by day 28. Patients were classified into tertiles on the basis of SOMAscan protein measurements for the 25 proteins most differentially expressed. The association of serum levels of each protein with kidney recovery was further evaluated using logistic regression analysis. Higher serum levels of CXCL11, CXCL2/CXCL3, CD86, Wnt-7a, BTK, c-Myc, TIMP-3, CCL5, ghrelin, PDGF-C, survivin, CA2, IL-9, EGF, and neuregulin-1, and lower levels of soluble CXCL16, IL1RL1, stanniocalcin-1, IL-6, and FGF23 when classified in tertiles were significantly associated with better kidney recovery. This significant association persisted for each of these proteins after adjusting for potential confounding risk factors including age, sex, cardiovascular SOFA score, congestive heart failure, diabetes, modality of intensive dialysis treatment, cause of AKI, baseline serum creatinine, day 8 urine volume, and estimated 60-day mortality risk. Conclusions: These results suggest concerted changes between survival-related proteins and immune-regulatory chemokines in regulating angiogenesis, endothelial and epithelial remodeling, and kidney cell regeneration, illustrating potential mechanisms of kidney recovery. Thus, this study identifies potential novel predictive biomarkers of kidney recovery in patients with AKI-D.
- 24 November 2020
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 22 (2) , 148-157
Characterization of Phosphorylated Proteins Using Mass Spectrometry
: Phosphorylation is arguably the most important post-translational modification that occurs within proteins. Phosphorylation is used as a signal to control numerous physiological activities ranging from gene expression to metabolism. Identifying phosphorylation sites within proteins was historically a challenge as it required either radioisotope labeling or the use of phospho-specific antibodies. The advent of mass spectrometry (MS) has had a major impact on the ability to qualitatively and quantitatively characterize phosphorylated proteins. In this article, we describe MS methods for characterizing phosphorylation sites within individual proteins as well as entire proteome samples. The utility of these methods is illustrated in examples that show the information that can be gained using these MS techniques.
- 24 November 2020
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 22 (2) , 148-157
Characterization of Phosphorylated Proteins Using Mass Spectrometry
: Phosphorylation is arguably the most important post-translational modification that occurs within proteins. Phosphorylation is used as a signal to control numerous physiological activities ranging from gene expression to metabolism. Identifying phosphorylation sites within proteins was historically a challenge as it required either radioisotope labeling or the use of phospho-specific antibodies. The advent of mass spectrometry (MS) has had a major impact on the ability to qualitatively and quantitatively characterize phosphorylated proteins. In this article, we describe MS methods for characterizing phosphorylation sites within individual proteins as well as entire proteome samples. The utility of these methods is illustrated in examples that show the information that can be gained using these MS techniques.
- Open Access
- 26 September 2019
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 127 (5) , 1349-1359
Exercise training upregulates Nrf2 protein in the rostral ventrolateral medulla of mice with heart failure
Chronic heart failure (CHF) is associated with global oxidative stress, which contributes to sympathoexcitation. Increased reactive oxygen species in the brain accumulate within neurons and lead to enhanced neuronal excitability. Exercise training (ExT) is associated with a reduction of oxidative stress by upregulation of antioxidant enzymes. The link between ExT and antioxidant enzyme expression in the brain of animals with CHF is not clear. We hypothesized that ExT enhances transcription and translation of the nuclear factor erythroid 2-related factor 2 (Nrf2) gene, a master transcription factor that modulates antioxidant enzyme gene expression, in the rostral ventrolateral medulla (RVLM) of mice with CHF. Mice were divided into the following groups: Sham sedentary (Sham-Sed), Sham-ExT, CHF-Sed, and CHF-ExT. After 8 wk of ExT, we measured Nrf2 and NAD(P)H dehydrogenase [quinone] 1 (NQO-1) message and protein expression along with maximal exercise tolerance and urinary norepinephrine (NE) excretion. We found that Nrf2 and NQO-1 mRNA and protein expression in the RVLM were lower in CHF-Sed mice compared with Sham-Sed. ExT attenuated the CHF-induced reduction of Nrf2 and NQO-1 mRNA and protein expression in the RVLM. NE excretion was higher in CHF-Sed mice compared with Sham-Sed (666.8 ± 79.3 ng/24 h, n = 6 vs. 397.8 ± 43.7 ng/24 h, P = 0.04). CHF-ExT mice exhibited reduced urinary NE excretion compared with CHF-Sed (360.7 ± 41.7 ng, n = 4 vs. 666.8 ± 79.3 ng, n = 6; P = 0.03). We conclude that ExT-induced upregulation of Nrf2 in the RVLM contributes to the beneficial effects of ExT on sympathetic function in the heart failure state. NEW & NOTEWORTHY This study provide evidence for an important role for exercise training in the modulation of antioxidant enzyme production in the rostral ventrolateral medulla (RVLM) in the heart failure state. We show here a correlation between exercise training and the expression of the antioxidant transcription factor Nrf2 in the RVLM. Exercise training reduced sympathetic function (norepinephrine excretion) and upregulated both Nrf2 and the antioxidant enzyme NQO-1. We conclude that Nrf2 in the RVLM may be an important target for controlling sympathetic outflow in heart failure.
- 26 September 2019
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 127 (5) , 1349-1359
Open AccessExercise training upregulates Nrf2 protein in the rostral ventrolateral medulla of mice with heart failure
Chronic heart failure (CHF) is associated with global oxidative stress, which contributes to sympathoexcitation. Increased reactive oxygen species in the brain accumulate within neurons and lead to enhanced neuronal excitability. Exercise training (ExT) is associated with a reduction of oxidative stress by upregulation of antioxidant enzymes. The link between ExT and antioxidant enzyme expression in the brain of animals with CHF is not clear. We hypothesized that ExT enhances transcription and translation of the nuclear factor erythroid 2-related factor 2 (Nrf2) gene, a master transcription factor that modulates antioxidant enzyme gene expression, in the rostral ventrolateral medulla (RVLM) of mice with CHF. Mice were divided into the following groups: Sham sedentary (Sham-Sed), Sham-ExT, CHF-Sed, and CHF-ExT. After 8 wk of ExT, we measured Nrf2 and NAD(P)H dehydrogenase [quinone] 1 (NQO-1) message and protein expression along with maximal exercise tolerance and urinary norepinephrine (NE) excretion. We found that Nrf2 and NQO-1 mRNA and protein expression in the RVLM were lower in CHF-Sed mice compared with Sham-Sed. ExT attenuated the CHF-induced reduction of Nrf2 and NQO-1 mRNA and protein expression in the RVLM. NE excretion was higher in CHF-Sed mice compared with Sham-Sed (666.8 ± 79.3 ng/24 h, n = 6 vs. 397.8 ± 43.7 ng/24 h, P = 0.04). CHF-ExT mice exhibited reduced urinary NE excretion compared with CHF-Sed (360.7 ± 41.7 ng, n = 4 vs. 666.8 ± 79.3 ng, n = 6; P = 0.03). We conclude that ExT-induced upregulation of Nrf2 in the RVLM contributes to the beneficial effects of ExT on sympathetic function in the heart failure state. NEW & NOTEWORTHY This study provide evidence for an important role for exercise training in the modulation of antioxidant enzyme production in the rostral ventrolateral medulla (RVLM) in the heart failure state. We show here a correlation between exercise training and the expression of the antioxidant transcription factor Nrf2 in the RVLM. Exercise training reduced sympathetic function (norepinephrine excretion) and upregulated both Nrf2 and the antioxidant enzyme NQO-1. We conclude that Nrf2 in the RVLM may be an important target for controlling sympathetic outflow in heart failure.
- 12 September 2019
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 18 (10) , 3661-3670
Stability of the Human Plasma Proteome to Pre-analytical Variability as Assessed by an Aptamer-Based Approach
Variable processing and storage of whole blood and/or plasma are potential confounders in biomarker development and clinical assays. The goal of the study was to investigate how pre-analytical variables impact the human plasma proteome. Whole blood obtained from 16 apparently healthy individuals was collected in six EDTA tubes and processed randomly under six pre-analytical variable conditions including blood storage at 0°C or RT for 6h (B6h0C or B6hRT) before processing to plasma, plasma storage at 4°C or RT for 24h (P24h4C or P24hRT), low centrifugal force at 1,300 xg, (Lowxg), and immediate processing to plasma under 2,500 xg (control) followed by plasma storage at -80°C. An aptamer-based proteomic assay was performed to identify significantly changed proteins (fold change ≥ 1.2, P < 0.05, and FDR < 0.05) relative to the control from a total of 1305 proteins assayed. Pre-analytical conditions Lowxg and B6h0C resulted in the most plasma proteome changes with 200 and 148 proteins significantly changed, respectively. Only 36 proteins were changed under B6hRT. Conditions P24h4C and P24hRT yielded changes of 28 and 75 proteins, respectively. The complement system was activated in vitro under the conditions B6hRT, P24h4C, and P24hRT. The results suggest particular pre-analytical variables should be controlled for clinical measurement of specific biomarkers.
- 12 September 2019
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 18 (10) , 3661-3670
Stability of the Human Plasma Proteome to Pre-analytical Variability as Assessed by an Aptamer-Based Approach
Variable processing and storage of whole blood and/or plasma are potential confounders in biomarker development and clinical assays. The goal of the study was to investigate how pre-analytical variables impact the human plasma proteome. Whole blood obtained from 16 apparently healthy individuals was collected in six EDTA tubes and processed randomly under six pre-analytical variable conditions including blood storage at 0°C or RT for 6h (B6h0C or B6hRT) before processing to plasma, plasma storage at 4°C or RT for 24h (P24h4C or P24hRT), low centrifugal force at 1,300 xg, (Lowxg), and immediate processing to plasma under 2,500 xg (control) followed by plasma storage at -80°C. An aptamer-based proteomic assay was performed to identify significantly changed proteins (fold change ≥ 1.2, P < 0.05, and FDR < 0.05) relative to the control from a total of 1305 proteins assayed. Pre-analytical conditions Lowxg and B6h0C resulted in the most plasma proteome changes with 200 and 148 proteins significantly changed, respectively. Only 36 proteins were changed under B6hRT. Conditions P24h4C and P24hRT yielded changes of 28 and 75 proteins, respectively. The complement system was activated in vitro under the conditions B6hRT, P24h4C, and P24hRT. The results suggest particular pre-analytical variables should be controlled for clinical measurement of specific biomarkers.